🏠 Home
Teaching
📚 All Courses Molecular Therapeutics (MOLD-405) Cell & Molecular Biology Special Topics Biomedical Sciences Syllabi 👤 About Me 🎓 CV / Download 📄 Publications 🛠 Services 🔬 Lab Resources ✍️ Blog 🎓 Student Portal ✉️ Contact 🌐 العربية
Icon-based summary: a scanner, a brain section, a biopsy tool and a microscope show the study design (61 patients, 472 samples); PET versus MRI sensitivity 91.2 versus 52.6 percent, specificity 82.5 versus 73.0, positive predictive value 97.1 versus 92.7 and negative predictive value 59.1 versus 19.2; tumor in 171 of 174 PET-positive non-enhancing samples and in 34.8 percent of PET-negative non-enhancing samples
The main results as reported in the paper (illustration prepared for this brief, not a figure from the paper). PET positive means a tumor-to-background ratio of 1.6 or more. Icons from the Reactome Icon Library (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/), NIH BioArt and other CC0 icons (via SciIcons), arranged and labeled by the author.

Surgeons and radiation oncologists plan around the part of a glioblastoma that lights up on contrast-enhanced MRI, but the tumor often extends beyond it. A team at LMU Munich and partner centers now reports that PET with the amino acid tracer O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) found far more tumor tissue than MRI in 472 tissue samples, each checked under the microscope.

Key numbers
Measure (472 samples, 61 patients)[18F]FET PETContrast-enhanced MRI
Sensitivity91.2%52.6%
Specificity82.5%73.0% (p = 0.146)
Positive predictive value97.1%92.7%
Negative predictive value59.1%19.2%
Tumor in PET-positive, non-enhancing tissue171 of 174 (98.3%)Not applicable

Why the question matters

Glioblastoma, IDH wildtype, is the most common malignant brain tumor in adults, and the extent of resection is one of its strongest prognostic factors. MRI shows a tumor when the blood-brain barrier is disrupted and a contrast agent leaks in, so infiltrating tumor without enhancement can be missed. T2/FLAIR MRI shows more, but changes such as edema and scarring also light up. The authors note that earlier studies reported larger tumor volumes on amino acid PET, but histology-verified data with many sampling sites were scarce.

How the study was done

From October 2019 to July 2025, 147 patients with suspected glioma were enrolled prospectively at one center. This analysis includes the 61 whose tumor was confirmed as IDH-wildtype glioblastoma: 45 newly diagnosed and 16 recurrent. All had MRI and [18F]FET PET before surgery. Targets were chosen on the coregistered scans in four kinds of areas: enhancing and PET-positive (area A), non-enhancing and PET-positive (area B), enhancing and PET-negative (area C), and neither (area D). PET-positive meant a tumor-to-background ratio of 1.6 or more. Samples came from stereotactic biopsy in 26 patients and from resection in 35, were tracked by navigation coordinates, and were graded by a neuropathologist blinded to clinical data as no tumor, infiltration zone or solid tumor. There were 472 samples in all: 210 from area A, 174 from B, 22 from C and 66 from D.

What PET found that MRI did not

PET uptake was present in all 61 patients, while contrast enhancement was present in 56. Across all samples, PET had a sensitivity of 91.2% against 52.6% for MRI (p below 0.001), with similar specificity (82.5% against 73.0%, p = 0.146). Positive predictive value was 97.1% for PET and 92.7% for MRI, and negative predictive value was 59.1% against 19.2%. In area B, where MRI showed no enhancement, 171 of 174 samples held tumor (98.3%). In area D, neither modality was positive and 34.8% of samples still held tumor. In 39 of 56 patients with an enhancing tumor (69.6%), PET signal extended at least 10 mm past the enhancing margin. In the five patients with no enhancement at all, all 30 area B samples held tumor.

Density and T2/FLAIR

In tumor-containing samples, PET detected 82.3% of those in the infiltration zone against 43.2% for MRI, and 99.1% of solid tumor against 60.8%. The PET signal rose with tumor burden (Spearman correlation 0.58). T2/FLAIR was less specific than PET. Among samples that were non-enhancing and PET-negative but T2/FLAIR-positive, only 37.0% (17 of 46) held tumor.

What the authors suggest

They propose that PET could guide supramarginal resection and radiotherapy target definition beyond the enhancing margin, and that PET-based response criteria could be used in follow-up, and they call for prospective trials. They note that a recent trial (GLIAA) found no outcome advantage for PET-based over MRI-based target delineation in re-irradiation of recurrent glioblastoma, and that this finding should be read cautiously.

Keep in mind

This is a single-center exploratory study. Sampling was targeted and opportunistic, with several samples per patient, and PET-negative tissue was under-sampled because extra biopsies carry risk, so the negative predictive value of 59.1% limits conclusions about tissue without PET signal. Recurrent disease was a small subgroup with no area D samples, and brain shift during surgery could have affected the match between images and samples. The study shows that PET is more sensitive for finding tumor tissue; it does not show that using PET in surgery or radiotherapy improves survival.

Original paper
Paper
Stürzl R, Kirchleitner SV, Lorenz J, Schmidbauer KJ, Stöcklein V, Quach S, et al. [18F]FET PET enables histopathology-validated detection of non-contrast-enhancing glioblastoma. Nature Communications. 2026;17(1). Published November 6, 2026.
Type
Prospective single-center exploratory diagnostic study
DOI
10.1038/s41467-026-78980-1
PubMed
PMID 42995172
Funding
Deutsche Forschungsgemeinschaft (DFG) research unit FOR-2858 (project numbers 421887978, 422188432, 403161218 and 422179811) and the Thomas Kirch Stiftung; the funders had no role in the study. Several authors report honoraria, advisory roles or research funding from companies, including Telix Pharmaceuticals and Novocure; the full statement is in the paper.
Dr. Abdelmuhsen Abusneina
Abdelmuhsen Abusneina, PhDAssociate Professor
Research focus: Molecular Oncology and Cancer Metabolism
Department of Molecular Diagnostics, Faculty of Biomedical Sciences, University of Benghazi, Libya

Weekly digest

The week's briefs and science news in one email. See the privacy policy.

← Back to the blog